Novotech Identifies Strategic Opportunities in Idiopathic Pulmonary Fibrosis Trials with Release of Global Market Insights
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF). The report offers strategic insights and comprehensive analysis critical for biotech and pharmaceutical companies navigating the complexities of IPF clinical research and drug development.
Novotech, a globally recognized CRO has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis.
Share
Advancing IPF Clinical Research: A Global Perspective
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by the scarring of lung tissue and a steady decline in respiratory function, most commonly affecting individuals between the ages of 60 and 70. Novotech's latest report identifies more than 800 industry-sponsored IPF clinical trials launched globally since 2020, reflecting strong research momentum and a growing commitment across the biotech and pharmaceutical sectors to address the increasing burden of this serious condition.
Key insights:
Global Clinical Trial Activity: The Asia-Pacific region accounts for the largest share of global IPF clinical trials at 44%, primarily driven by significant activity in Mainland China. North America follows with 23%, led by the United States, while Europe contributes 21%, with notable trial concentration in the United Kingdom and Germany.
Emerging Therapeutic Innovations: The development pipeline is advancing with novel therapeutic approaches, including RNA interference (RNAi)-based therapies, PDE4 inhibitors, cell-based treatments, and monoclonal antibodies—signaling promising progress in IPF management and patient outcomes.
Advancements in Trial Design and Biomarkers: Precision medicine and patient-centric trial methodologies, coupled with the integration of key biomarkers, are improving diagnostic accuracy, disease monitoring, and the assessment of therapeutic efficacy in IPF studies.
Investment and Funding Landscape: Strong venture capital activity is fueling early- and mid-stage IPF drug development, particularly in the United States and Europe. Public-sector contributions, including funding from the EU Horizon 2020 program and the U.S. Department of Defense, are also instrumental in supporting innovation.
Addressing Racial and Ethnic Disparities: The report highlights the critical need for greater diversity in IPF clinical trials and calls for equitable care strategies and targeted education to reduce treatment disparities across racial and ethnic populations.
Partnering with Novotech for IPF Clinical Trials
With extensive expertise in pulmonary and respiratory diseases, Novotech offers biotech and pharmaceutical partners an accelerated path to market. The company's comprehensive capabilities include therapeutic expertise, regulatory guidance, and strategic clinical trial execution, supported by its expansive global footprint across Asia-Pacific, North America, and Europe.
Download the Full Report
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member, visit www.Novotech-CRO.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CATalyst Council Unveils 2025 Feline Market Insights Report Volume II: $12 Billion Market Reveals $20 Billion Opportunity to Close the Feline Care Gap
ANNAPOLIS, Md., June 16, 2025--(BUSINESS WIRE)--The CATalyst Council, the veterinary industry's leading authority on the feline market, released Volume II of its 2025 Feline Market Insights Report. This data-driven resource offers an in-depth examination of U.S. feline healthcare dynamics, owner behaviors, and veterinary trends, highlighting a $12 billion market that has been growing approximately 9% on average per year in recent years. Despite overall pet healthcare visits declining over the last three years, cats have enjoyed sustained visit and pricing growth, underscoring the compelling, scalable opportunity that, until now, has remained undiscovered within the broader long-term "pet boom." The report confirms that, while the canine segment has dominated revenue in size, feline practice revenue has had higher average annual growth over the past 5 years. Beyond that, the current US total addressable feline veterinary market (TAM) remains at more than 2.5 times its current size, or an incremental $20 billion growth opportunity. This feline TAM simply assumes that cats reach the same rate of medicalization and level of care per visit as dogs presently enjoy. "The growth we see in feline visits today, combined with favorable pet age demographics and an ongoing recovery in US real per capita income points to an exceptional growth opportunity arising in today's pet healthcare market," said Jon Ayers, CATalyst Council board member and chair of its Market Insights Committee. "Understanding feline species-specific stress responses and caregiver mindsets is critical," said Kristin Wuhrman, Vice Chair of the CATalyst Council. "By addressing costs, perceptions of value, and visit-related anxiety, adopting FelineVMA's Cat Friendly Practice care protocols, and educating caregivers on cat behavior, we can overcome key barriers and deepen the bond between cats, caregivers, and clinics, ultimately ensuring more cats receive the care they need." Volume II delivers the strategic playbook that practices, consolidators, industry suppliers, and investors need to build their investment plans: Key Findings $12 Billion Feline Veterinary Market with approximately 9% average annual growth: In 2024, feline practice revenue reached an estimated $11.7 billion, up from $7.6 billion in 2019, outpacing canine average annual growth (estimated at 7.5%, with 2024 US canine veterinary market of $48 billion). Unmet Medicalization Gap: Only an estimated 30% of U.S. household-owned cats received a visit to a veterinary practice in 2024, compared to a corresponding estimated 65–70% for dogs. Practice-Level Revenue Opportunity: Closing the care gap to match canine medicalization could expand the addressable market from $12 billion to $32 billion, adding an average of $680,000 (approximately 33%) to annual revenue to the average two-million-dollar U.S. veterinary practice location. "Addressing the feline care gap should be a call to action for the entire animal health community," adds Anne Ward, Chair of CATalyst Council. "The feline veterinary segment has come of age with the opportunity for greater species-specific innovation by the industry and care profession." Recovery Forecast: CATalyst projects that pet age demographic headwinds faced in the last three years as a result of the aging and mortality of pets adopted during the depressed years of 2009-2011 following the 2008 great financial crisis, could turn to tailwinds as pets adopted from 2013 onwards reach their geriatric years, beginning in late 2025 or 2026. As the median lifespan of a cat is a little over 14 years, and correspondingly 13 years for a dog, these last few years of pet age are when visits are the highest after the first year of life. "Pet demographics are hard trends and as inevitable as pet mortality and practice taxes," said Jane Brunt DVM, proactive feline practice owner and CATalyst Council Executive Director. This tailwind, combined with the potential for continued consumer inflation-adjusted income recovery, would accelerate feline visit growth and help reverse canine visit declines, starting in the next 6 to 18 months. Looking Ahead: Data-Driven Validation Building on these insights, CATalyst Council plans to field a 30,000 US-household "State of the Cat" survey in late 2025. This extensive, statistically robust study will drill into regional, demographic, and behavioral nuances, enabling early adopters to pilot hyper-targeted programs and measure ROI against validated owner and feline needs. The 2025 CATalyst Feline Market Insights Reports, released quarterly and available exclusively to CATalyst Council sponsors, will inform each phase. CATalyst plans to share high-level conclusions throughout the year via press releases and LinkedIn, ensuring veterinary professionals, industry stakeholders, and decision-makers receive evidence-based updates. To receive updates or inquire about the benefits of sponsorship, please visit and follow Catalyst Council on LinkedIn. About CATalyst Council CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond. View source version on Contacts FOR MORE INFORMATION Jane Brunt, Phone: 410-627-7921 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
an hour ago
- Business Wire
CATalyst Council Unveils 2025 Feline Market Insights Report Volume II: $12 Billion Market Reveals $20 Billion Opportunity to Close the Feline Care Gap
ANNAPOLIS, Md.--(BUSINESS WIRE)--The CATalyst Council, the veterinary industry's leading authority on the feline market, released Volume II of its 2025 Feline Market Insights Report. This data-driven resource offers an in-depth examination of U.S. feline healthcare dynamics, owner behaviors, and veterinary trends, highlighting a $12 billion market that has been growing approximately 9% on average per year in recent years. Despite overall pet healthcare visits declining over the last three years, cats have enjoyed sustained visit and pricing growth, underscoring the compelling, scalable opportunity that, until now, has remained undiscovered within the broader long-term 'pet boom.' "CATalyst Council is a 501(c)(3) nonprofit coalition of leaders in veterinary medicine, animal welfare, and the pet industry. It drives innovation in feline care by analyzing U.S. feline healthcare dynamics, owner behaviors, and veterinary trends." The report confirms that, while the canine segment has dominated revenue in size, feline practice revenue has had higher average annual growth over the past 5 years. Beyond that, the current US total addressable feline veterinary market (TAM) remains at more than 2.5 times its current size, or an incremental $20 billion growth opportunity. This feline TAM simply assumes that cats reach the same rate of medicalization and level of care per visit as dogs presently enjoy. ' The growth we see in feline visits today, combined with favorable pet age demographics and an ongoing recovery in US real per capita income points to an exceptional growth opportunity arising in today's pet healthcare market,' said Jon Ayers, CATalyst Council board member and chair of its Market Insights Committee. 'Understanding feline species-specific stress responses and caregiver mindsets is critical,' said Kristin Wuhrman, Vice Chair of the CATalyst Council. 'By addressing costs, perceptions of value, and visit-related anxiety, adopting FelineVMA's Cat Friendly Practice care protocols, and educating caregivers on cat behavior, we can overcome key barriers and deepen the bond between cats, caregivers, and clinics, ultimately ensuring more cats receive the care they need.' Volume II delivers the strategic playbook that practices, consolidators, industry suppliers, and investors need to build their investment plans: Key Findings $12 Billion Feline Veterinary Market with approximately 9% average annual growth: In 2024, feline practice revenue reached an estimated $11.7 billion, up from $7.6 billion in 2019, outpacing canine average annual growth (estimated at 7.5%, with 2024 US canine veterinary market of $48 billion). Unmet Medicalization Gap: Only an estimated 30% of U.S. household-owned cats received a visit to a veterinary practice in 2024, compared to a corresponding estimated 65–70% for dogs. Practice-Level Revenue Opportunity: Closing the care gap to match canine medicalization could expand the addressable market from $12 billion to $32 billion, adding an average of $680,000 (approximately 33%) to annual revenue to the average two-million-dollar U.S. veterinary practice location. 'Addressing the feline care gap should be a call to action for the entire animal health community,' adds Anne Ward, Chair of CATalyst Council. 'The feline veterinary segment has come of age with the opportunity for greater species-specific innovation by the industry and care profession.' Recovery Forecast: CATalyst projects that pet age demographic headwinds faced in the last three years as a result of the aging and mortality of pets adopted during the depressed years of 2009-2011 following the 2008 great financial crisis, could turn to tailwinds as pets adopted from 2013 onwards reach their geriatric years, beginning in late 2025 or 2026. As the median lifespan of a cat is a little over 14 years, and correspondingly 13 years for a dog, these last few years of pet age are when visits are the highest after the first year of life. 'Pet demographics are hard trends and as inevitable as pet mortality and practice taxes,' said Jane Brunt DVM, proactive feline practice owner and CATalyst Council Executive Director. This tailwind, combined with the potential for continued consumer inflation-adjusted income recovery, would accelerate feline visit growth and help reverse canine visit declines, starting in the next 6 to 18 months. Looking Ahead: Data-Driven Validation Building on these insights, CATalyst Council plans to field a 30,000 US-household 'State of the Cat' survey in late 2025. This extensive, statistically robust study will drill into regional, demographic, and behavioral nuances, enabling early adopters to pilot hyper-targeted programs and measure ROI against validated owner and feline needs. The 2025 CATalyst Feline Market Insights Reports, released quarterly and available exclusively to CATalyst Council sponsors, will inform each phase. CATalyst plans to share high-level conclusions throughout the year via press releases and LinkedIn, ensuring veterinary professionals, industry stakeholders, and decision-makers receive evidence-based updates. To receive updates or inquire about the benefits of sponsorship, please visit and follow Catalyst Council on LinkedIn. CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond.
Yahoo
2 hours ago
- Yahoo
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure RAHWAY, N.J., June 12, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore. "Approximately half of the world's population live in areas with a risk for dengue, making it a serious public health threat," said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. "The initiation of the MOBILIZE-1 study, the first Phase 3 trial in our clinical development program, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe." Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat. About MOBILIZE-1 (NCT07013487)MOBILIZE-1, also known as V181-005, is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization. For more information on the trial, visit About V181V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections. About Dengue diseaseDengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. With approximately half of the world's population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. Dengue fever might evolve to severe dengue, formerly known as dengue hemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death. About MerckAt Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USAThis news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( View source version on Contacts Media Contacts:Olivia Finucane0044 7881 Kimberly Petrillo(267) 742-2813kimberly_petrillo@ Investor Contacts:Peter Dannenbaum(732) Damini Chokshi(732) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
